Evogene (NASDAQ:EVGN) Announces Earnings Results

Evogene (NASDAQ:EVGN) issued its earnings results on Thursday. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78, Zacks reports. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. During the same period in the prior year, the company earned ($1.30) earnings per share.

Evogene Stock Performance

Shares of EVGN stock traded down $0.01 during midday trading on Thursday, reaching $1.41. 27,026 shares of the company were exchanged, compared to its average volume of 89,095. The company’s 50 day moving average price is $1.59 and its two-hundred day moving average price is $2.09. The company has a market cap of $7.54 million, a P/E ratio of -0.31 and a beta of 1.29. Evogene has a 12 month low of $1.20 and a 12 month high of $10.00.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Evogene in a research note on Sunday. They set a “sell” rating for the company.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.